CEO of Doudna spinout: Within five years, genome editors will have a 'really big impact' on patients' lives
Endpoints News
|
August 12, 2022
X min read
Endpoints News
|
August 12, 2022
Share on Social
More like this
Media
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
Press
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
